The LHRH antagonist Cetrorelix: A review

Human Reproduction Update

Volumn 6, Issue 4, 2000, Pages 322-331

  Reissmann, T ^a   Schally, A V ^b   Bouchard, P ^c   Riethmuller H ^a   Engel, J ^a  

^a ASTA MEDICA AG   (Germany)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Benign prostatic hyperplasia; Cancer treatment; GnRH antagonist; Gonadotrophins; Ovarian stimulation

Indexed keywords

BUSERELIN; CETRORELIX; FOLLITROPIN; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; GONADOTROPIN; HORMONE RECEPTOR; ITURELIX; LUTEINIZING HORMONE; PLACEBO; SEX HORMONE; TESTOSTERONE; TRIPTORELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; ENDOMETRIOSIS; FEMALE; FERTILIZATION IN VITRO; FIBROMA; FOLLITROPIN RELEASE; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; LUTEINIZING HORMONE RELEASE; MALE; MONKEY; NONHUMAN; OVARY CANCER; OVARY FUNCTION; OVULATION INDUCTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RAT; UTERUS TUMOR;

EID: 0033849284     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/6.4.322     Document Type: Article

References (58)

1. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation
2. 3H]thymidine uptake by luteinizing hormone-releasing hormone agonists: A possible mechanism for preventing damage by cytotoxic agents
3. Phase I study of Cetrorelix s.c. to determine tolerability and efficacy of testosterone suppression in previously untreated patients with advanced prostatic carcinoma
4. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues
5. Selection and characterization of mammalian cell lines with stable over-expression of human pituitary receptors for gonadoliberin
6. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist Cetrorelix (SB-75) in normal men
7. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist Cetrorelix (SB-75) in normal men
8. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men
9. Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75
10. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75)
11. Efficacy and safety of luteinizing hormone-releasing hormone antagonists Cetrorelix in the treatment of symptomatic benign prostatic hyperplasia
12. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
13. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers
14. First results of the GnRH-antagonist Cetrorelix in patients with ovarian cancer
15. Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes
16. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility
17. Treatment of uterine fibroids with a slow-release formulation of the gonadotropin releasing hormone antagonist Cetrorelix
18. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: Agonists and antagonists
19. Responses to the antagonistic analog of LHRH (Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer
20. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)
21. Luteinizing hormone-releasing hormone antagonist Cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord
22. Treatment of patients with advanced prostate cancer with LHRH antagonist Cetrorelix
23. Treatment of uterine leiomyomas with LHRH antagonist Cetrorelix
24. 6)-LHRH
25. Pharmacokinetics and Pharmacodynamics of the LHRH antagonist Cetrorelix in healthy male and female subjects
26. Hormonal responses to the new potent GnRH antagonist Cetrorelix
27. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (buserelin) as a new therapeutic approach for endometriosis
28. A randomized double blind placebo controlled phase II study of the safety and efficacy of Cetrorelix in men with BPH
29. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: Further evidence for the role of GnRH during the LH surge
30. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone
31. Differing responses of plasma bioactive and immunoactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women
32. Hormonal stimulation of the recovery of spermatogenesis following chemo- or radiotherapy
33. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program
34. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: A pilot study
35. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist
36. The use of a GnRH antagonist (Cetrorelix(R)) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg
37. 6-LHRH in rats by a highly potent LHRH antagonist Cetrorelix
38. 6 forms of the LHRH antagonist Cetrorelix (SB-75)
39. The LHRH Anatgonist Cetrorelix
40. Pharmacological studies with Cetrorelix (SB-75), a potent antagonist of luteinizing hormone-releasing hormone
41. Novel antagonsits of GnRH: A compendium of their physiochemical properties, activities, relative potencies and efficacy in humans
42. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): A pilot study with minimal stimulation
43. LHRH Analogues: Their impact on the control of tumorigenesis
44. LHRH Analogues: I. Their impact on reproductive medicine
45. Use of LH-RH analogs for the treatment of prostate cancer: Combination therapy and direct effects
46. Hypothalamic FSH and LH-regulating hormone: Structure, physiology and clinical studies
47. Analogs of LHRH: The present and the future
48. 6)-LH-RH, A potent antagonist of LH-RH, produces transient edema and behavioral changes in rats
49. Basic and clinical aspects of GnRH-agonists in reproduction
50. Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice
51. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization
52. Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women
53. 6] luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer
54. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75
55. Evaluation of the antigonadotropic activity of different GnRH antagonists in the non-human primate
56. Gonadotrophin releasing hormone analog-induced regulation of testicular function in monkeys and men
57. Can testosterone alone maintain the gonadotrophin-releasing hormone antagonist-induced suppression of spermatogenesis in the non-human primate?
58. Effect of luteinizing hormone releasing hormone analogs on the rat ovarian follicle development